Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...
We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at ...
Christophe Weber will step down as CEO of Takeda next year, the company announced Thursday, following a drop-off in its share price over the last couple of years. Weber, 59, has led the Japanese ...
TOKYO, Jan 30 (Reuters) - Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as ...
OSAKA, Japan, January 30, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024 ...
Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.
When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant. When Takeda CEO ...
Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.
Takeda Pharmaceutical 4502-0.74%decrease; red down pointing triangle named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but ...
Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences. Osavampator, formerly known as NBI ...
Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board DirectorSeasoned regulatory strategist Darren ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results